Determining the risk of human anti-human antibodies in...

Details Determining the risk of human anti-human antibodies in... Determining the risk of human anti-human antibodies in...

2005-05-23

2009-12-01

Sajjadi, Fereydoun G (Department: 1633)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

C800S018000, C800S009000

Reexamination Certificate

active

07625549

ABSTRACT:
The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

REFERENCES:
patent: 4998931 (1991-03-01), Slichter et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5595598 (1997-01-01), Yooda et al.
patent: 5612205 (1997-03-01), Berns et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Choi et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5698405 (1997-12-01), Goldenberg
patent: 5721367 (1998-02-01), Berns et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5981175 (1999-11-01), Loring et al.
patent: 6023010 (2000-02-01), Krimpenfort
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6114598 (2000-09-01), Kucherlapati
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6255458 (2001-07-01), Lonberg et al.
patent: 6258562 (2001-07-01), Salfeld et al.
patent: 6652863 (2003-11-01), Jordan et al.
patent: 2003/0229207 (2003-12-01), Studnicka
patent: 2004/0005630 (2004-01-01), Studnicka
patent: 2004/0018191 (2004-01-01), Wang et al.
patent: 2005/0260679 (2005-11-01), Kellermann et al.
patent: 0 463 151 (1992-01-01), None
patent: 546 073 (1997-10-01), None
patent: 3 068 180 (1991-03-01), None
patent: 3 068 506 (1991-03-01), None
patent: 3 068 507 (1991-03-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/22645 (1992-12-01), None
patent: WO 92/22647 (1992-12-01), None
patent: WO 92/22670 (1992-12-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 94/02602 (1994-03-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 96/14436 (1996-05-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/13852 (1997-04-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 98/24893 (1998-11-01), None
patent: WO 00/76310 (2000-12-01), None
patent: WO 01/31065 (2001-05-01), None
patent: WO 03/047336 (2003-06-01), None
Wiener, L. J. Immunother. 29:1-9; 2006 (pp. 1-14).
Tangri et al. (Curr. Med. Chem. 9:2191-2199; 2002.
Kellermann et al. Developing the Xenomouse technology for evaluating immunogenicity. Retrieved from the Internet Mar. 23, 2004, from http://diagnosticscrc.org/publications/brochures/Antib0Z-2.pdf.
Roskos et al. Human Antiglobulin Responses.Measuring Immunity, 2005, 172-186, ed. Lotze and Thomas.
Wilson et al. “Somatic Hypermutation Introduces Insertions and Deletions in to Immunoglobulin V Genes,” J Exp. Med. 1998, 187:59-70.
Slide presentation, “Abgenix: Dedicated to developing novel antibody therapeutics,” presented by Larry L. Green in Australia, not prior to Mar. 21, 2004.
International Preliminary Report on Patentability, International Application No. PCT/US2005/009306, mailed Sep. 28, 2006, 7 pages.
International Search Report and Written Opinion of the International Searching Authority, International Application No. PCT/US2005/009306, mailed Feb. 9, 2006, 11 pages.
International Preliminary Report on Patentablity, International Application No. PCT/US2005/018143, mailed Dec. 7, 2006, 10 pages.
International Search Report and Written Opinion of the International Searching Authority, International Application No. PCT/US2005/018143, mailed Feb. 14, 2006, 13 pages.
Communication pursuant to Article 96(2) EPC, received in EP Application No. 05 725 970.7-1222, dated Aug. 6, 2007, 2 pages.
Communication Pursuant to Article 94(3) EPC; received in European Patent Application No. 05727870.7; dated Oct. 1, 2008.
Krause et al. “Human monoclonal antibody 99mTc-88BV59: detection of colorectal cancer, recurrent of metastatic disease and immunogenicity assessment,” European Journal of Nuclear Medicine, Vol. 24, No. 1, Jan. 1997.
Office Action dated Dec. 31, 2008, received in U.S. Appl. No. 11/084,554.
Glas et al., “Motif-specific probes identify individual genes and detect somatic mutations,” Molecular Immunology, 1999, pp. 599-610, vol. 36, Elsevier Science Ltd.
Huang et al., “VHusage and somatic hypermutation in peripheral blood B cells of patients with rheumatoid arthritis (RA),” Clin Exp Immunol, 1998, pp. 516-527, vol. 112, Blackwell Science.
Meffre et al., “Circulating human B cells that express surrogate light chains display a unique antibody repertoire,” Abs of V-PREB+L+B Cells Show Self-Reactivity Features, 2001, pp. 2150-2156, The American Association of Immunologists.
Suleyman et al., “Molecular analysis of human immunoglobulin heavy chain variable region associated determinants recognized by anti-VH3 antibodies 7B4, B6 and D12,” Scand. J. Immunol., 2000, pp. 341-347, vol. 52, Blackwell Science, Ltd.
U.S. Appl. No. 07/574,748, filed Aug. 29, 1990, GenPharm International.
U.S. Appl. No. 07/575,962, filed Aug. 31, 1990, GenPharm International.
U.S. Appl. No. 07/810,279, filed Dec. 17, 1991, GenPharm International.
U.S. Appl. No. 07/853,408, filed Mar. 18, 1992, GenPharm International.
U.S. Appl. No. 07/919,297, filed Jul. 24, 1992, Kucherlapati et al.
U.S. Appl. No. 07/922,649, filed Jul. 30, 1992, Kucherlapati et al.
U.S. Appl. No. 07/990,860, filed Dec. 16, 1992, GenPharm International.
U.S. Appl. No. 08/031,131, filed Apr. 26, 1993, GenPharm International.
U.S. Appl. No. 08/031,801, filed Mar. 15, 1993, Kucherlapati et al.
U.S. Appl. No. 08/096,762, filed Jul. 22, 1993, GenPharm International.
U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.
U.S. Appl. No. 08/155,301, filed Nov. 18, 1993, GenPharm International.
U.S. Appl. No. 08/161,739, filed Dec. 3, 1993, GenPharm International.
U.S. Appl. No. 08/165,699, filed Dec. 10, 1993, GenPharm International.
U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.
U.S. Appl. No. 08/309,741, filed Mar. 9, 1994, GenPharm International.
U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.
U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.
U.S. Appl. No. 08/462,513, filed Jun. 5, 1995, Seong- Min K.
U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/464,582, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/724,752, filed Oct. 2, 1996, Kucherlapati et al.
U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Mendez et al.
U.S. Appl. No. 08/904,068, filed Jun. 23, 1992, GenPharm International.
U.S. Appl. No. 11/136,250, filed May 23, 2005, Kellermann et al.
U.S. Appl. No. 60/430,729, filed Dec. 2, 2002, Babcook et al.
Atkinson et al., Immunogenetics, 44(2), 115-120 (1996).
Babcook et al., Selected Lymphocyte Antibody Method, Proc. Natl. Acad. Sci. USA, i93:7843-7848 (1996).
Brezinschek et al., J. Immunol., 155:190-202 (1995).
Demaison et al., Immunogenetics., 42:342-352 (1995).
Dijk-Hard et al., Immunology, 107:136-133 (2002).
Dijk-Hard et al., J Autoimmune. 12:57-63 (1999).
Ebeling et al., Int Immunol., 4:313-320 (1992).
Feuchtenberger et al., J Immunol Methods, 276:121-127 (2003).
Green et al., J. Exp. Med. 188:483-495 (1998).
Green et al., Nature

Affiliated with

Also associated with

Rating

Determining the risk of human anti-human antibodies in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Determining the risk of human anti-human antibodies in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determining the risk of human anti-human antibodies in... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4149202